The cost‐effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa

Introduction Many HIV‐positive individuals in Africa have advanced disease when initiating antiretroviral therapy (ART) so have high risks of opportunistic infections and death. The REALITY trial found that an enhanced‐prophylaxis package including fluconazole reduced mortality by 27% in individuals...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the International AIDS Society 2020-03, Vol.23 (3), p.e25469-n/a
Hauptverfasser:	Cox, Edward, Revill, Paul, Bwakura‐Dangarembizi, Mutsa, Mallewa, Jane, Cheruiyot, Priscilla, Gibb, Diana M, Walker, A Sarah, Kityo, C, Wavamunno, P, Nambi, E, Ocitti, P, Ndigendawani, M, Kabahenda, S, Acen, J, Nambaziira, F, Kabaswahili, V, Abach, J, Omongin, J, Philliam, A, Ocung, E, Miles, P, Adong, C, Kidega, P, Mukuye, A, Baliruno, D, Kigongo, F, Kikyonkyo, D, Mushahara, F, Okweny, D, Atwongyeire, D, Mula, S, Noowe, N, Lugemwa, A, Kyomuhangi, J, Ankunda, R, Ayesiga, L, Nathoo, K, Reid, A, Tinago, GC, Mudzingwa, S, Phiri, M, Musoro, G, Nemasango, B, Moyo, C, Chitongo, S, Mlambo, B, Ndemera, B, Agutu, C, Berkley, J, Maitland, K, Wale, S, Shangala, J, Kithunga, J, Mutai, R, Mwanzu, A, Latham, H, Shikuku, J, Mwakisha, B, Siika, A, Wools‐Kaloustian, K, Nyandiko, W, Meli, B, Mokaya, M, Mboya, C, Mengich, C, Choge, J, Injera, W, Njenga, K, Cherutich, S, Anyango Orido, M, Kutto, I, Shali, A, Pierre, M, Van Oosterhout, J, Heydermann, R, Dzabala, N, Ziwoya, M, Masesa, C, Mwalukomo, T, Bwanali, J, Thomason, M, Pett, S, Little, E, Cowan, F, Bernays, S, Mupambireyi, Z, Kyomuhendo, F, Nakalanzi, S, Mkandawire, N, Matandika, L, Kapuya, C, Malianga, E, Gibb, D, Etyang, A, Phiri, S, Lyall, H, Fitzgerald, F, Prendergast, A, Arenas‐Pinto, A, Turkova, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adolescent Adult Africa AIDS AIDS-Related Opportunistic Infections - economics AIDS-Related Opportunistic Infections - prevention & control Analysis Anti-HIV Agents - administration & dosage Anti-HIV Agents - economics Anti-HIV Agents - therapeutic use Antifungal agents Antifungal Agents - administration & dosage Antifungal Agents - therapeutic use Antigens, Fungal - analysis Antiretroviral agents Bacterial infections Care and treatment CD4 Lymphocyte Count Child Child, Preschool Cohort Studies Cost benefit analysis Costs cost‐effectiveness Cryptococcus - immunology Diagnosis Drug dosages Drug therapy Economic aspects Evaluation Female Fluconazole Fluconazole - therapeutic use Health aspects Highly active antiretroviral therapy HIV HIV infection HIV Infections - drug therapy HIV Infections - economics HIV Infections - mortality HIV Infections - prevention & control Human immunodeficiency virus Humans Infections Kenya late‐presenters Malawi Male Meningitis Mortality Post-Exposure Prophylaxis - economics Practice guidelines (Medicine) Prophylaxis Quality-Adjusted Life Years Strategic planning (Business) Sub-Saharan Africa Tuberculosis Uganda United Kingdom Zimbabwe
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction Many HIV‐positive individuals in Africa have advanced disease when initiating antiretroviral therapy (ART) so have high risks of opportunistic infections and death. The REALITY trial found that an enhanced‐prophylaxis package including fluconazole reduced mortality by 27% in individuals starting ART with CD4
ISSN:	1758-2652 1758-2652
DOI:	10.1002/jia2.25469